Mersana Therapeutics, Inc. Income (Loss) from Continuing Operations, Per Basic and Diluted Share
Mersana Therapeutics, Inc. reported Income (Loss) from Continuing Operations, Per Basic and Diluted Share of -$6.33 per share for the 3-month period ending 2017-06-30, per its 10-Q filed 2017-08-11.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare · last filed 2017-08-11
- Mersana Therapeutics, Inc. income (loss) from continuing operations, per basic and diluted share for the quarter ending 2017-06-30 was -$6.33.
- Mersana Therapeutics, Inc. income (loss) from continuing operations, per basic and diluted share for the quarter ending 2016-06-30 was -$3.00.
| Period end | Income (Loss) from Continuing Operations, Per Basic and Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Basic and Diluted Share 6 month |
|---|---|---|
| 2017-06-30 | -$6.33 10-Q · filed 2017-08-11 | -$12.36 10-Q · filed 2017-08-11 |
| 2016-06-30 | -$3.00 10-Q · filed 2017-08-11 | -$7.31 10-Q · filed 2017-08-11 |